Skip to main content

Table 2 Efficacy endpoints at week 16 using non-responder imputation

From: Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Endpoints

Secukinumab IV-300 mg (N = 76)

Secukinumab IV-150 mg (N = 74)

Placebo (N = 76)

ASAS20, n (%)

46 (60.5)§

43 (58.1)‡

28 (36.8)

ASAS40, n (%)

32 (42.1)‡

30 (40.5)‡

16 (21.1)

hsCRP (post-baseline/baseline ratio), mean change from baseline ± SE

0.48 ± 1.1‡

0.55 ± 1.1‡

1.09 ± 1.1

ASAS 5/6, n (%)

30 (39.5)‡

31 (41.9)‡

11 (14.5)

BASDAI, mean change from baseline ± SE

-2.7 ± 0.3‡

-2.3 ± 0.3‡

-1.5 ± 0.3

ASAS partial remission, n (%)

16 (21.1)‡

7 (9.5)

1 (1.3)

  1. Non-responder imputation (binary variables) and mixed-model repeated measures (continuous variables) data are presented
  2. ASAS20 20% response according to criteria of the Assessment of Spondyloarthritis International Society, ASAS40 40% response according to ASAS criteria, hsCRP high-sensitivity C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index
  3. ASAS Assessment of SpondyloArthritis international Society, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, hsCRP high-sensitivity C-reactive protein, N number of patients, SE standard error
  4. ‡ P < 0.05, § P < 0.01 vs placebo. P values were adjusted for multiplicity of testing